financetom
Business
financetom
/
Business
/
Klotho Neurosciences (KLTO) Stock Surges Over 680%: What's Going On?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Klotho Neurosciences (KLTO) Stock Surges Over 680%: What's Going On?
Jun 9, 2025 9:21 AM

Shares of Klotho Neurosciences Inc ( KLTO ) skyrocketed over 680% to $1.60 during Monday morning trading after the company highlighted promising pre-clinical study findings for its anti-aging therapy.

What To Know: The biogenetics firm announced that elevating the expression of the Klotho gene could potentially reduce age-related degeneration across multiple organs, thereby increasing both lifespan and health span.

This announcement draws on research published in the February 2025 edition of Molecular Therapy. The study demonstrated that a secreted form of the Klotho protein (s-KL), when administered via an AAV9 vector, led to a 20% increase in the lifespan of mice.

Read Also: GameStop Stock Volatile Ahead Of Earnings, Boosted By Bitcoin Bet And Switch 2 Hype

These findings bolster the therapeutic potential of s-KL in combating age-associated conditions like cognitive decline and neuroinflammation.

Klotho Neurosciences ( KLTO ) holds an exclusive worldwide license for this s-KL technology from Universitat Autònoma de Barcelona and Institució Catalana de Recerca i Estudis Avançats.

CEO Dr. Joseph Sinkule stated, “This recently published paper provides further credence to our development of s-KL as a treatment to reduce age-associated degeneration.”

The company is particularly focused on applying this research to neurodegenerative diseases such as ALS, Alzheimer’s, and Parkinson’s, with the original discoverer of the Klotho gene, Professor Makoto Kuro-O, serving as a scientific advisor.

Read Also: Robinhood Stock Is Falling Monday: What’s Going On?

How To Buy KLTO Stock

By now you're likely curious about how to participate in the market for Klotho Neurosciences ( KLTO ) – be it to purchase shares, or even attempt to bet against the company.

Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy “fractional shares,” which allows you to own portions of stock without buying an entire share.

If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to “go short” a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.

According to data from Benzinga Pro, KLTO has a 52-week high of $5.11 and a 52-week low of $0.12.

Image: Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Brazil Inc places cautious bet on Argentina turnaround under Milei
Brazil Inc places cautious bet on Argentina turnaround under Milei
Feb 17, 2025
SAO PAULO (Reuters) - Brazilian companies are scoping out acquisition targets in Argentina, while beefing up staff and stores in a cautious bet on President Javier Milei's aggressive economic reforms that are beginning to stabilize the crisis-stricken economy. Brazilian firms, including consumer goods, services, oil and tech, told Reuters they are looking to launch new ventures or drafting expansion plans...
Dutch pension fund ABP sells all Alphabet and Meta shares, CEO tells newspaper FD
Dutch pension fund ABP sells all Alphabet and Meta shares, CEO tells newspaper FD
Feb 17, 2025
AMSTERDAM, Feb 17 (Reuters) - ABP, the Netherlands' largest pension fund, has sold its shares in tech companies Meta and Alphabet, its CEO told Dutch newspaper FD in an interview published on Monday. CEO Harmen van Wijnen said the companies no longer fit the fund's governance criteria. FD reported last month that ABP had sold its shares in Tesla for...
Russia fines Google for YouTube clip telling Russian troops how to surrender, TASS says
Russia fines Google for YouTube clip telling Russian troops how to surrender, TASS says
Feb 17, 2025
MOSCOW, Feb 17 (Reuters) - A Russian court has fined Alphabet's Google 3.8 million roubles ($41,530) for hosting content on YouTube that included videos instructing Russian soldiers how to surrender, Russia's TASS news agency reported on Monday. Russia has for several years ordered foreign technology platforms to remove content it deems illegal, such as what it calls fakes about the...
Teva Pharm CEO calls on Trump for faster US drug approvals
Teva Pharm CEO calls on Trump for faster US drug approvals
Feb 17, 2025
* Says supplies generic drugs in US cost effectively * Says produces high volumes in the US * Bullish on future earnings on basis of innovative portfolio (Adds quotes from news conference, context, paragraph 7 onwards) By Steven Scheer TEL AVIV, Feb 17 (Reuters) - U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some...
Copyright 2023-2026 - www.financetom.com All Rights Reserved